 Home > Medical News > Latest Medical News > Hengrui Carrelizumab is approved by the FDA for Phase III clinical trials in the U.S.

Hengrui Carrelizumab is approved by the FDA for Phase III clinical trials in the U.S.

 Last Update: 2021-08-29
 Source: Internet
 Author: User

Tags

anti mitochondrial antibody

drug interaction tool

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Today, Hengrui Pharmaceuticals announced that it has received a letter from the US FDA regarding the approval of the use of carrelizumab for injection in combination with famitinib malate capsules for the phase III clinical trial of advanced non-small cell lung cancer

The approved clinical trial is a randomized controlled trial of carrelizumab combined with famitinib versus docetaxel in the treatment of advanced non-small cell lung cancer that has failed previous platinum-based chemotherapy and immune checkpoint inhibitors.

Carrelizumab for injection is a PD-1 inhibitor independently developed by Hengrui Pharmaceuticals.

Famitinib malate capsules are small molecule multi-target tyrosine kinase inhibitors innovatively developed by Hengrui Pharmaceuticals and are currently undergoing clinical development in China and the United States

Preliminary clinical studies have shown that carrelizumab for injection combined with famitinib malate capsules are effective in treating a variety of tumors including cervical cancer, ovarian cancer, renal cell carcinoma, and non-small cell lung cancer

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.